文献速递胸部肿瘤

雌激素促进NSCLC小鼠模型对贝伐珠单抗的耐药

Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-07-24

该研究在NSCLC人源异种移植模型中探讨雌激素对肿瘤生长、血管生成及贝伐珠单抗(BV)疗效的影响。结果显示雌激素诱导对BV的明显耐药,伴肿瘤血管周细胞覆盖率增加2.3倍(p=0.01)及VEGF和PDGF-BB上调;雌激素还使肿瘤浸润髓系细胞募集增加逾两倍(p=0.001),伴G-CSF和CXCL1升高。使用氟维司群阻断雌激素受体通路可重新致敏肿瘤对VEGF靶向治疗的反应,表现为肿瘤血管减少和总生存期延长。

要点

  • 雌激素可诱导NSCLC模型对贝伐珠单抗耐药。
  • 耐药机制可能涉及周细胞覆盖增加和髓系细胞募集。
  • 氟维司群阻断雌激素受体可恢复对VEGF靶向治疗的敏感性。

核心结论

  • 雌激素可能通过增强周细胞覆盖和髓系细胞募集促进对VEGF靶向治疗的耐药。
  • 雌激素受体阻断值得进一步研究作为增强抗血管生成治疗效果的策略。

研究设计与样本

  • 研究采用NSCLC人源异种移植模型,探讨雌激素对肿瘤生长、血管生成及贝伐珠单抗反应的影响。

主要发现

  • 雌激素诱导对贝伐珠单抗的明显耐药,伴肿瘤血管周细胞覆盖率增加2.3倍(p=0.01)。
  • 雌激素上调促血管生成因子VEGF和血小板衍生生长因子-BB。
  • 雌激素使肿瘤浸润髓系细胞募集增加逾两倍(p=0.001),伴髓系募集因子G-CSF和CXCL1升高。
  • 氟维司群阻断雌激素受体通路可重新致敏肿瘤对VEGF靶向治疗的反应,表现为肿瘤血管减少和总生存期延长。

临床怎么用

  • 在NSCLC抗血管生成治疗中,可考虑评估雌激素受体通路状态及雌激素水平对疗效的潜在影响。
  • 雌激素受体阻断(如氟维司群)可能作为增强抗血管生成治疗效果的潜在策略,但需进一步临床研究验证。

局限性

  • 研究基于人源异种移植小鼠模型,结论需在临床研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Subgroup analyses from clinical studies have suggested that among patients with metastatic NSCLC receiving chemotherapy, females may derive less benefit from the addition of the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (BV) than males. This has raised the question of whether estrogen may affect the response to antiangiogenic therapy. METHODS: To address this, we investigated the effects of estrogen on tumor growth, angiogenesis, and the response to BV in human xenograft models of NSCLC. RESULTS: We observed that estrogen induced marked resistance to BV, which was accompanied by a 2.3-fold increase in tumor vascular pericyte coverage (p = 0.01) and an up-regulation of proangiogenic factors, VEGF and platelet-derived growth factor-BB. We also investigated the role of infiltrating myeloid cells, a population that has been associated with resistance to anti-VEGF therapies. We observed that estrogen induced a greater than twofold increase (p = 0.001) in the recruitment of tumor-infiltrating myeloid cells and concomitant increases in the myeloid recruitment factors, G-CSF and CXCL1. Blockade of the estrogen receptor pathway using fulvestrant resensitized tumors to VEGF targeting as evidenced by reduced tumor vasculature and an increase in overall survival in our NSCLC xenograft models. CONCLUSIONS: Collectively, these data provide evidence that estrogen may promote resistance to VEGF-targeted therapies, potentially by enhancing pericyte coverage and myeloid recruitment, and suggest that estrogen receptor blockade merits further investigation as an approach to enhance the effects of antiangiogenic therapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Patel SA, Herynk MH, Cascone T, et al. Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. J Thorac Oncol. 2021. PMID: 34311109. doi:10.1016/j.jtho.2021.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。